MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$7,545K
Free Cash flow
-$25,842K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from sales and maturiti...
Proceeds from the issuance of co...
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Net loss
Operating lease liabilities
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-24,473
-27,937
-27,426
-27,892
Stock-based compensation expense
2,433
2,488
3,521
3,460
Depreciation
908
932
1,049
932
Amortization of premiums and discounts on marketable securities
248
365
530
654
Loss on disposal of fixed assets
-105
-
-62
0
Non-cash lease expense
1,304
1,269
1,262
1,233
Accounts receivable
1,438
-267
-1,425
1,512
Related party collaboration receivable
71
-
-700
0
Prepaid expenses and other current assets
1,868
-471
-2,290
-3,153
Other non-current assets
214
-
-
-
Accounts payable
-1,109
-2,290
2,897
312
Accrued expenses
979
-5,126
-3,185
2,831
Operating lease liabilities
-1,999
-1,933
-1,869
-1,836
Deferred revenue
-151
-1,195
-10,459
-11,075
Net cash used in operating activities
-25,842
-33,419
-30,263
-31,048
Purchases of property and equipment
0
14
626
207
Purchases of marketable securities
27,410
43,441
12,503
6,636
Proceeds from sales and maturities of marketable securities
42,801
51,556
60,553
201,418
Net cash provided by investing activities
15,391
8,101
47,424
34,888
Proceeds from the exercise of stock options
57
294
21
85
Proceeds from the purchase of common stock under espp
219
-
115
0
Proceeds from the issuance of common stock from at-the-market sales agreement, net of issuance costs
2,630
3,038
-
-
Net cash provided by financing activities
2,906
3,332
136
85
Net decrease in cash, cash equivalents, and restricted cash
-7,545
-21,986
17,297
3,925
Cash, cash equivalents, and restricted cash, beginning of period
46,050
68,036
50,739
74,241
Cash, cash equivalents, and restricted cash, end of period
38,505
46,050
68,036
50,739
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from sales and
maturities of marketable...
$42,801K
(-73.20%↓ Y/Y)
Proceeds from the
issuance of common stock...
$2,630K
Proceeds from the
purchase of common stock...
$219K
(-49.54%↓ Y/Y)
Proceeds from the
exercise of stock options
$57K
(-64.60%↓ Y/Y)
Net cash provided by
investing activities
$15,391K
(-64.32%↓ Y/Y)
Net cash provided by
financing activities
$2,906K
(388.40%↑ Y/Y)
Canceled cashflow
$27,410K
Net decrease in
cash, cash...
-$7,545K
(72.49%↑ Y/Y)
Canceled cashflow
$18,297K
Stock-based compensation
expense
$2,433K
(-68.83%↓ Y/Y)
Non-cash lease expense
$1,304K
(-45.12%↓ Y/Y)
Accrued expenses
$979K
(145.62%↑ Y/Y)
Depreciation
$908K
(-56.33%↓ Y/Y)
Loss on disposal of
fixed assets
-$105K
(-32.91%↓ Y/Y)
Purchases of marketable
securities
$27,410K
(-76.12%↓ Y/Y)
Net cash used in
operating activities
-$25,842K
(63.68%↑ Y/Y)
Canceled cashflow
$5,729K
Net loss
-$24,473K
(62.00%↑ Y/Y)
Operating lease
liabilities
-$1,999K
(43.24%↑ Y/Y)
Prepaid expenses and
other current assets
$1,868K
(2.30%↑ Y/Y)
Accounts receivable
$1,438K
(745.88%↑ Y/Y)
Accounts payable
-$1,109K
(49.41%↑ Y/Y)
Amortization of premiums and
discounts on marketable...
$248K
(-86.14%↓ Y/Y)
Other non-current
assets
$214K
Deferred revenue
-$151K
(97.92%↑ Y/Y)
Related party
collaboration receivable
$71K
(-59.43%↓ Y/Y)
Buy us a coffee
Voyager Therapeutics, Inc. (VYGR)
Voyager Therapeutics, Inc. (VYGR)